Mechanistic insight into the efficient osteogenic potential of dihydrotestosterone

Exploring sequential expression of bone-related protein biomarkers

Hnin Ei Thu, Zahid Hussain, Isa Naina Mohamed, Ahmad Nazrun Shuid

Research output: Contribution to journalArticle

Abstract

Numerous in vitro, in vivo and clinical studies have evidenced the outstanding potential of dihydrotestosterone (DHT) in the treatment of male osteoporosis. Despite of promising clinical efficacy of DHT in regulating the skeletal growth and homeostasis, the exact molecular and translational mechanism is yet to be explored. This study was aimed to investigate the bone-forming molecular mechanism of DHT using MC3T3-E1 cell line as in vitro model. The mechanism of bone-forming ability of DHT was assessed by evaluating the time-mannered expression of bone-related biomarkers such as bone morphogenic protein-2 (BMP-2), alkaline phosphatase (ALP), runt-related transcription factor 2 (Runx-2), osteocalcin (OCN), type I collagen, osteopontin (OPN), transforming growth factor-β1 (TGF-β1) and androgen receptor (AR). Results demonstrated a remarkable efficacy of DHT (at a dose of 0.1 ng/mL) in promoting the expression of these vital bone-forming mediators. The resulting analysis revealed that the DHT-0.1 group showed higher expression of BMP-2 (106±9 pg/mL), ALP (381±16 pg/mL), Runx-2 (664±32 pg/mL), OCN (2265±111 pg/mL), type I collagen (276±16 pg/mL), TGF-β1 (81±7 pg/mL) and AR (411±21 pg/mL) compared to the control (CN) and other DHT-treated groups. These findings provide an in vitro evidence for the bone-forming capacity of DHT and its therapeutic significance for the treatment of male osteoporosis.

Original languageEnglish
Pages (from-to)234-243
Number of pages10
JournalActa Medica Iranica
Volume56
Issue number4
Publication statusPublished - 1 Jan 2018

Fingerprint

Dihydrotestosterone
Biomarkers
Bone and Bones
Proteins
Osteocalcin
Androgen Receptors
Transforming Growth Factors
Collagen Type I
Osteoporosis
Alkaline Phosphatase
Osteopontin
Growth Factor Receptors
Homeostasis
Transcription Factors
Cell Line
Growth

Keywords

  • Bone-related biomarkers
  • Cell proliferation
  • Dihydrotestosterone
  • Enhanced osteogenesis
  • Osteoporosis
  • Time mannered expression

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{871796b7a49c4766bd06868b883e5954,
title = "Mechanistic insight into the efficient osteogenic potential of dihydrotestosterone: Exploring sequential expression of bone-related protein biomarkers",
abstract = "Numerous in vitro, in vivo and clinical studies have evidenced the outstanding potential of dihydrotestosterone (DHT) in the treatment of male osteoporosis. Despite of promising clinical efficacy of DHT in regulating the skeletal growth and homeostasis, the exact molecular and translational mechanism is yet to be explored. This study was aimed to investigate the bone-forming molecular mechanism of DHT using MC3T3-E1 cell line as in vitro model. The mechanism of bone-forming ability of DHT was assessed by evaluating the time-mannered expression of bone-related biomarkers such as bone morphogenic protein-2 (BMP-2), alkaline phosphatase (ALP), runt-related transcription factor 2 (Runx-2), osteocalcin (OCN), type I collagen, osteopontin (OPN), transforming growth factor-β1 (TGF-β1) and androgen receptor (AR). Results demonstrated a remarkable efficacy of DHT (at a dose of 0.1 ng/mL) in promoting the expression of these vital bone-forming mediators. The resulting analysis revealed that the DHT-0.1 group showed higher expression of BMP-2 (106±9 pg/mL), ALP (381±16 pg/mL), Runx-2 (664±32 pg/mL), OCN (2265±111 pg/mL), type I collagen (276±16 pg/mL), TGF-β1 (81±7 pg/mL) and AR (411±21 pg/mL) compared to the control (CN) and other DHT-treated groups. These findings provide an in vitro evidence for the bone-forming capacity of DHT and its therapeutic significance for the treatment of male osteoporosis.",
keywords = "Bone-related biomarkers, Cell proliferation, Dihydrotestosterone, Enhanced osteogenesis, Osteoporosis, Time mannered expression",
author = "Thu, {Hnin Ei} and Zahid Hussain and {Naina Mohamed}, Isa and Shuid, {Ahmad Nazrun}",
year = "2018",
month = "1",
day = "1",
language = "English",
volume = "56",
pages = "234--243",
journal = "Acta Medica Iranica",
issn = "0044-6025",
publisher = "Teheran University of Medical Sciences",
number = "4",

}

TY - JOUR

T1 - Mechanistic insight into the efficient osteogenic potential of dihydrotestosterone

T2 - Exploring sequential expression of bone-related protein biomarkers

AU - Thu, Hnin Ei

AU - Hussain, Zahid

AU - Naina Mohamed, Isa

AU - Shuid, Ahmad Nazrun

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Numerous in vitro, in vivo and clinical studies have evidenced the outstanding potential of dihydrotestosterone (DHT) in the treatment of male osteoporosis. Despite of promising clinical efficacy of DHT in regulating the skeletal growth and homeostasis, the exact molecular and translational mechanism is yet to be explored. This study was aimed to investigate the bone-forming molecular mechanism of DHT using MC3T3-E1 cell line as in vitro model. The mechanism of bone-forming ability of DHT was assessed by evaluating the time-mannered expression of bone-related biomarkers such as bone morphogenic protein-2 (BMP-2), alkaline phosphatase (ALP), runt-related transcription factor 2 (Runx-2), osteocalcin (OCN), type I collagen, osteopontin (OPN), transforming growth factor-β1 (TGF-β1) and androgen receptor (AR). Results demonstrated a remarkable efficacy of DHT (at a dose of 0.1 ng/mL) in promoting the expression of these vital bone-forming mediators. The resulting analysis revealed that the DHT-0.1 group showed higher expression of BMP-2 (106±9 pg/mL), ALP (381±16 pg/mL), Runx-2 (664±32 pg/mL), OCN (2265±111 pg/mL), type I collagen (276±16 pg/mL), TGF-β1 (81±7 pg/mL) and AR (411±21 pg/mL) compared to the control (CN) and other DHT-treated groups. These findings provide an in vitro evidence for the bone-forming capacity of DHT and its therapeutic significance for the treatment of male osteoporosis.

AB - Numerous in vitro, in vivo and clinical studies have evidenced the outstanding potential of dihydrotestosterone (DHT) in the treatment of male osteoporosis. Despite of promising clinical efficacy of DHT in regulating the skeletal growth and homeostasis, the exact molecular and translational mechanism is yet to be explored. This study was aimed to investigate the bone-forming molecular mechanism of DHT using MC3T3-E1 cell line as in vitro model. The mechanism of bone-forming ability of DHT was assessed by evaluating the time-mannered expression of bone-related biomarkers such as bone morphogenic protein-2 (BMP-2), alkaline phosphatase (ALP), runt-related transcription factor 2 (Runx-2), osteocalcin (OCN), type I collagen, osteopontin (OPN), transforming growth factor-β1 (TGF-β1) and androgen receptor (AR). Results demonstrated a remarkable efficacy of DHT (at a dose of 0.1 ng/mL) in promoting the expression of these vital bone-forming mediators. The resulting analysis revealed that the DHT-0.1 group showed higher expression of BMP-2 (106±9 pg/mL), ALP (381±16 pg/mL), Runx-2 (664±32 pg/mL), OCN (2265±111 pg/mL), type I collagen (276±16 pg/mL), TGF-β1 (81±7 pg/mL) and AR (411±21 pg/mL) compared to the control (CN) and other DHT-treated groups. These findings provide an in vitro evidence for the bone-forming capacity of DHT and its therapeutic significance for the treatment of male osteoporosis.

KW - Bone-related biomarkers

KW - Cell proliferation

KW - Dihydrotestosterone

KW - Enhanced osteogenesis

KW - Osteoporosis

KW - Time mannered expression

UR - http://www.scopus.com/inward/record.url?scp=85045155142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045155142&partnerID=8YFLogxK

M3 - Article

VL - 56

SP - 234

EP - 243

JO - Acta Medica Iranica

JF - Acta Medica Iranica

SN - 0044-6025

IS - 4

ER -